ISRCTN ISRCTN29462550
DOI https://doi.org/10.1186/ISRCTN29462550
Secondary identifying numbers NTR248
Submission date
20/12/2005
Registration date
20/12/2005
Last edited
13/10/2014
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Dr D. Oepkes
Scientific

Leiden University Medical Centre
Department of Obstetrics
K6-31, P.O. Box 9600
Leiden
2300 RC
Netherlands

Phone +31 (0)71 5263360
Email D.Oepkes@lumc.nl

Study information

Study designMulticentre randomised single-centre active-controlled parallel-group trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific titleIntravenous immunoglobulin (IvIG) in the treatment of foetal or neonatal alloimmune thrombocytopenia: a prospective, multicentre, randomised trial comparing 0.5 g and 1.0 g IvIG per kilogram bodyweight per week
Study acronymNOICH (No IntraCranial Haemorrhage)
Study objectivesThe hypothesis is that 0.5 g/kg/wk of IvIG is as effective as 1.0 g/kg/wk, in the prevention of intracranial haemorrhage (ICH) in foetal or neonatal alloimmune thrombocytopenia (FNAIT).
Ethics approval(s)Ethics approval received from the local medical ethics committee
Health condition(s) or problem(s) studiedFoetal or neonatal alloimmune thrombocytopenia
InterventionStudy group: low dose IvIG (0.5 g/kg/wk)
control group: standard treatment: high dose IvIG (1.0 g/kg/wk)
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Intravenous immunoglobulin (IvIG)
Primary outcome measureNumber of neonates with intracranial haemorrhage.
Secondary outcome measures1. Cord blood platelet count at birth
2. Other variables studied will be the levels of maternal and neonatal anti-HPA antibodies and IgG, the occurrence of other bleedings in the neonate as well as the necessity and type of neonatal treatment
Overall study start date01/01/2005
Completion date30/01/2008

Eligibility

Participant type(s)Patient
Age groupAdult
SexFemale
Target number of participants212
Key inclusion criteria1. Pregnant women with a subsequent pregnancy after prior pregnancy complicated by HPA alloimmunisation who have given birth to a child with a platelet count less than 150 x 10^9/l in the first week of life
2. HPA alloimmunisation must have been confirmed by the presence of maternal anti-HPA antibodies and the offending HPA antigen in the foetus or homozygous partner
3. The biological fathers are either homozygous positive for the HPA-type or heterozygous
4. In the case of a heterozygous father the platelet antigen genotype of the foetus will be tested before 28 weeks by amniocentesis
5. At inclusion, the pregnancy is an ultrasonographically proven intrauterine singleton pregnancy with a gestational age between 12 and 28 weeks
6. All participating patients will give written informed consent after oral and written trial information
Key exclusion criteria1. Pregnant women with autoimmune thrombocytopenia
2. Twins or multiple pregnancies
3. Foetuses and neonates with major congenital anomalies or chromosomal abnormalities
4. Women who have previously given birth to children with FNAIT with ICH
5. Women who have antibodies in the first pregnancy (discovered by chance, or for instance with a sister with FNAIT)
Date of first enrolment01/01/2005
Date of final enrolment30/01/2008

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Leiden University Medical Centre
Leiden
2300 RC
Netherlands

Sponsor information

Leiden University Medical Centre (LUMC) (Netherlands)
University/education

Albinusdreef 2
P.O. Box 9600
Leiden
2300 RC
Netherlands

Website http://www.lumc.nl/
ROR logo "ROR" https://ror.org/027bh9e22

Funders

Funder type

Research organisation

Sanquin Bloodbank Amsterdam (The Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan